Loading...

Home
ETF
IMNN

IMNN

-

$

0.000

0.000(0.000%)

At close

0.000(0.000%)Aft-market

ET

$

0.000

0.000(0.000%)

At close

0.000(0.000%)Aft-market

ET

Overview Technical News

Most Trusted AI Platform for Winning Trades

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

Home
Contact
About Us
Press
Privacy
Terms of Service
Service Terms of Use

Resources

Blog
Tutorial
Help Center
Affiliate Program

Markets

Market Analysis
Crypto
Featured Screeners
AI Earnings Calendar
Market Movers
Stock Monitor
Economic Calendar
All US Stocks
All Cryptos

Tools

Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator

Features

QuantAI Alpha Pick
SwingMax Portfolio
Swing Trading
AI Stock Picker
Whales Auto Tracker
Daytrading Center
Patterns Detection
AI Screener
Financial AI Agent
Backtesting Playground
AI Earnings Prediction
Stock Monitor
Technical Analysis

News

Overview
Top News
Daily Market Brief
Earnings Analysis
Newswire
Stock News
Crypto News
Institution News
Congress News
Monitor News

Compare

TradingView
SeekingAlpha

IMNN News

IMUNON Secures $7 Million from Institutional Investor in Direct Stock Offering

Dec 30 2025Newsfilter

IMUNON Advances OVATION3 Study, Aiming for Breakthrough Therapy

Dec 29 2025Globenewswire

IMUNON Advances OVATION3 Study, Aiming for Breakthrough Therapy

Dec 29 2025Newsfilter

Imunon (IMNN) Q3 2025 Earnings Conference Call Transcript

Nov 13 2025NASDAQ.COM

IMUNON Releases Financial Results for Q3 2025 and Offers Business Update

Nov 13 2025Newsfilter

IMUNON's Public Webcast Showcases Resilience and Innovation in the Quest for the First Approved Ovarian Cancer Immunotherapy

Nov 10 2025Newsfilter

IMUNON R&D Day: Chance to Listen to Clinical Trial Researchers Discuss the Promising Impact of IMNN-001 on Ovarian Cancer Therapy

Nov 07 2025Newsfilter

VTYX, MEDP, INBX Surge in After-Hours Trading Following Important Announcements

Oct 23 2025NASDAQ.COM

IMUNON Holds R&D Day Showcasing Advances in OVATION 3 Study Aiming for First-Line Immunotherapy for Advanced Ovarian Cancer

Oct 20 2025Newsfilter

IMUNON to Showcase New Translational Data for IMNN-001 in Support of Phase 3 Ovarian Cancer Immunotherapy Trial at AACR Special Conference on Cancer Research

Sep 19 2025Newsfilter

IMUNON Achieves Compliance with Nasdaq's Minimum Bid Price Requirement

Aug 28 2025Newsfilter

Imunon Inc (IMNN) Q2 2025 Earnings Call Highlights: Strategic Advances Amid Financial Challenges

Aug 06 2025Yahoo Finance

IMUNON (IMNN) Stock Is Trending Wednesday: What's Going On?

Jul 30 2025Benzinga

IMUNON Granted Continued Listing Extension by Nasdaq to Complete Compliance Plan

Jul 15 2025Newsfilter

IMUNON Announces PlaCCine® DNA Vaccine Technology Abstract Selected for Oral Presentation at 10th International Conference on Vaccines Research & Development™

Jun 17 2025Newsfilter

Life Sciences Investor Forum: Now Available for Online Viewing

Jun 13 2025Newsfilter